Insulin Glargine Concept

subject area of

• A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs  Journal Articles
• A Glycemic Threshold Above Which the Improvement of β-Cell Function and Glycemia in Response to Insulin Therapy Is Amplified in Early Type 2 Diabetes: The Reversal of Glucotoxicity.  Journal Articles
• A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose‐lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study  Journal Articles
• Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia  Journal Articles
• Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial  Journal Articles
• Biomarkers of Prevalent and Incident Cognitive Dysfunction in People with Dysglycemia: Data from the ORIGIN Trial  Journal Articles
• Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial.  Journal Articles
• Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE)  Journal Articles
• Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial  Journal Articles
• Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study  Journal Articles
• Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial  Journal Articles
• Cost implications of the use of basal insulin glargine in people with early dysglycemia: The ORIGIN trial  Journal Articles
• Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes  Journal Articles
• Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial  Journal Articles
• Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study  Journal Articles
• Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial  Journal Articles
• Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization  Journal Articles
• Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events  Journal Articles
• Effect of basal insulin and omega 3 fatty acids on cognitive impairment in dysglycaemia: An exploratory analysis of the ORIGIN trial  Journal Articles
• Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial  Journal Articles
• Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes  Journal Articles
• Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta‐analysis  Journal Articles
• Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial  Journal Articles
• Effects of basal insulin glargine and omega‐3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial  Journal Articles
• Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes  Journal Articles
• Growth Differentiation Factor 15 as a Novel Biomarker for Metformin  Journal Articles
• Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial  Journal Articles
• Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial  Journal Articles
• Identifying blood biomarkers for type 2 diabetes subtyping: a report from the ORIGIN trial  Journal Articles
• Insulin resistance and cardiovascular outcomes in the ORIGIN trial  Journal Articles
• Novel Biomarkers for Change in Renal Function in People With Dysglycemia  Journal Articles
• Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit  Journal Articles
• Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial  Journal Articles
• Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial  Journal Articles
• Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)  Journal Articles
• Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes  Journal Articles
• Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial  Journal Articles
• Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin  Journal Articles
• Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915–2922  Journal Articles
• Sex hormone-binding globulin and heart failure hospitalizations in patients with dysglycemia  Journal Articles
• Short‐term intensive insulin as induction and maintenance therapy for the preservation of beta‐cell function in early type 2 diabetes (RESET‐IT Main): A 2‐year randomized controlled trial  Journal Articles
• Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population  Journal Articles
• Testosterone and sex hormone-binding globulin in dysglycemic women at high cardiovascular risk: A report from the Outcome Reduction with an Initial Glargine Intervention trial  Journal Articles
• Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial  Journal Articles
• The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia  Journal Articles
• The association of basal insulin treatment versus standard care with outcomes in anti‐GAD positive and negative subjects: A post‐hoc analysis of the ORIGIN trial  Journal Articles
• The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial  Journal Articles
• Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study  Journal Articles
• Use of basal insulin in the management of adults with type 2 diabetes: An Asia‐Pacific evidence‐based clinical practice guideline  Journal Articles
• Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial  Conferences
• Vaspin: A Novel Biomarker Linking Gluteofemoral Body Fat and Type 2 Diabetes Risk  Journal Articles
• n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia  Journal Articles